Harvest Technologies selects Osteotech as exclusive U.S. distributor of its BMAC(TM) (Bone Marrow Aspirate Concentrate) System

Share Article

Harvest Technologies Corp. (http://www.harvesttech.com) announced today it has signed an exclusive distribution agreement related to its BMAC(TM) System in the US for the orthopedic bone regeneration market with Eatontown, N.J.-based Osteotech Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine. Harvest's BMAC (Bone Marrow Aspirate Concentrate) System is a point-of-care device for concentrating a patient's own (autologous) bone marrow stem cells. The BMAC(TM) System derives bone marrow aspirate concentrate, which is a rich source of autologous adult stem cells, in just 15 minutes.

News Image
We are very excited to be partnering with Osteotech. As a leader in the osteobiologic market, Osteotech is the perfect partner for our BMAC product. Our two technologies have the potential to set a new standard for bone regeneration

    The scientific literature establishes that successful bone regeneration is a combination of cells, signal proteins and a quality scaffold. The combination of Osteotech's biologic bone regeneration products with Harvest's BMAC will provide orthopedic surgeons a new powerful tool.

"We are very excited to be partnering with Osteotech. As a leader in the osteobiologic market, Osteotech is the perfect partner for our BMAC product. Our two technologies have the potential to set a new standard for bone regeneration," said Gary Tureski, President of Harvest Technologies.

Harvest Technologies has a rich tradition of innovative technologies that are designed to process and concentrate autologous cells and proteins. The BMAC system incorporates a proprietary floating-shelf technology that provides the highest total nuclear cell yield with established viability and osteogenicity. (1,2)

Until the introduction of Harvest's BMAC(TM) System, it was difficult to process and concentrate a clinically significant dose of adult stem cells from a patient's bone marrow at the point of patient care within 15 minutes.

Harvest Technologies is a privately held company based in Plymouth, Mass.

1 Osteogenic differentiation model, performed at the CBR Institute of Biomedical Research, Boston, 2006. 2 Heeschen, Christopher M.D, et al. Concentration of Bone Marrow Total Nucleated Cells by a Point of Care Device Provides a High Yield and Preserves Their Functional Activity. Cell Transplantation, Vol 16. pp-159-1069, 2008.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronald C. Trahan
Visit website